ENGAGE-501: Phase 2 Study Investigating the Role of Epigenetic Therapy with Entinostat (SNDX-275) In Relapsed and Refractory Hodgkin's Lymphoma (HL), Interim Results

被引：0
|
作者：
Younes, Anas [1 ]
Hernandez, Francisco [2 ,3 ]
Bociek, R. Gregory [4 ]
Kasamon, Yvette L. [5 ]
Lee, Peter [6 ]
Gore, Lia [7 ]
Buglio, Daniela [8 ]
Copeland, Amanda [9 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Clin Invest & Translat Res Dept Lymphoma Myeloma, Houston, TX 77030 USA
[2] Roswell Pk Canc Inst, Dept Med Oncol, Buffalo, NY 14263 USA
[3] Roswell Pk Canc Inst, Dept Immunol Canc Cell Ctr, Buffalo, NY 14263 USA
[4] Univ Nebraska Med Ctr, Dept Internal Med, Omaha, NE USA
[5] Johns Hopkins Univ, Baltimore, MD USA
[6] Tower Canc Res Fdn, Beverly Hills, CA USA
[7] Univ Colorado Canc Ctr, Aurora, CO USA
[8] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA
[9] Univ Texas Houston, MD Anderson Canc Ctr Hymphoma Myeloma, Houston, TX USA
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1614 / 1615
页数：2
相关论文
共 50 条
  • [21] Interim analysis of a phase II study of denileukin diftitox (Ontak) for relapsed/refractory T-cell non-Hodgkin's lymphoma.
    Dang, NH
    Pro, B
    Hagemeister, FB
    Jones, D
    Samuels, B
    Rodriguez, MA
    Goy, A
    Romaguera, JE
    Walker, PL
    Kwak, L
    Fayad, L
    BLOOD, 2004, 104 (11) : 722A - 722A
  • [22] Phase II study of EPOCH infusional chemotherapy in relapsed or refractory Hodgkin's lymphoma (HL). A report on toxicity, efficacy and prognostic indicators of outcome.
    Dunleavy, KM
    Butrynski, J
    Steinberg, S
    Grant, N
    White, T
    Jaffe, ES
    Wilson, WH
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 582S - 582S
  • [23] R2: Preliminary Results of a Phase II Study of Lenalidomide and Rituximab in Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (NHL)
    DeRook, Ian
    Odonnell, Robert T.
    Noble, B.
    Quirch, C.
    Tuscano, Joseph
    BLOOD, 2008, 112 (11) : 1052 - 1052
  • [24] R2: Preliminary Results of a Phase II Study of Lenalidomide and Rituximab in Relapsed Refractory Indolent Non-Hodgkin's Lymphoma (NHL).
    Dutia, Mrinal
    DeRoock, Ian
    Chee, Karen
    O'donnell, Robert
    Quirch, Christine
    Reed-Pease, Christine
    Tuscano, Joseph
    BLOOD, 2009, 114 (22) : 670 - 670
  • [25] UPDATED INTERIM RESULTS OF AN INTERNATIONAL, MULTICENTER, PHASE 2 STUDY OF IBRUTINIB (PCI-32765) IN RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA
    Rule, S.
    Wang, M.
    Martin, P.
    Auer, R.
    Kahl, B.
    Jurczak, W.
    Advani, R.
    Romaguera, J.
    Williams, M.
    Barrientos, J.
    Chmielowska, E.
    Radford, J.
    Stilgenbauer, S.
    Troung, V.
    McGreivy, J.
    Clow, F.
    Beaupre, D.
    Kunkel, L.
    Goy, A.
    Blum, K.
    HAEMATOLOGICA, 2013, 98 : 489 - 489
  • [26] CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results
    Jae H. Park
    Karthik Nath
    Sean M. Devlin
    Craig S. Sauter
    M. Lia Palomba
    Gunjan Shah
    Parastoo Dahi
    Richard J. Lin
    Michael Scordo
    Miguel-Angel Perales
    Roni Shouval
    Ana Alarcon Tomas
    Elizabeth Cathcart
    Elena Mead
    Bianca Santomasso
    Andrei Holodny
    Renier J. Brentjens
    Isabelle Riviere
    Michel Sadelain
    Nature Medicine, 2023, 29 : 1710 - 1717
  • [27] CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results
    Park, Jae H.
    Nath, Karthik
    Devlin, Sean M.
    Sauter, Craig S.
    Palomba, M. Lia
    Shah, Gunjan
    Dahi, Parastoo
    Lin, Richard J. J.
    Scordo, Michael
    Perales, Miguel-Angel
    Shouval, Roni
    Tomas, Ana Alarcon
    Cathcart, Elizabeth
    Mead, Elena
    Santomasso, Bianca
    Holodny, Andrei
    Brentjens, Renier J.
    Riviere, Isabelle
    Sadelain, Michel
    NATURE MEDICINE, 2023, 29 (07) : 1710 - +
  • [28] Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study
    Younes, Anas
    Sureda, Anna
    Ben-Yehuda, Dina
    Zinzani, Pier Luigi
    Ong, Tee-Chuan
    Prince, H. Miles
    Harrison, Simon J.
    Kirschbaum, Mark
    Johnston, Patrick
    Gallagher, Jennifer
    Le Corre, Christophe
    Shen, Angela
    Engert, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (18) : 2197 - 2203
  • [29] Preliminary results from a phase II study of lenalidomide monotherapy in Relapsed/Refractory aggressive non-Hodgkin's lymphoma.
    Wiemik, Peter H.
    Lossos, Izidore
    Tuscano, Joseph
    Justice, Glen
    Vose, Julie M.
    Pietronigro, Dennis
    Takeshita, Kenichi
    Ervin-Haynes, Annette
    Zeldis, Jerome B.
    Habermann, Thomas M.
    BLOOD, 2006, 108 (11) : 160A - 161A
  • [30] Early results from a phase II study of lenalidomide monotherapy in relapsed/refractory indolent non-Hodgkin's lymphoma.
    Wilzig, Thomas E.
    Vose, Julie M.
    Kaplan, Henry P.
    Wolf, Jeffrey Lee
    Pietronigro, Dennis
    Takeshita, Kenichi
    Ervin-Haynes, Annette
    Zeldis, Jerome B.
    Wiernik, Peter H.
    BLOOD, 2006, 108 (11) : 703A - 703A
12345